Founded on September , through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan Olmetec , launched in by Sankyo and now available in more than countries around the world the antiplatelet agent prasugrel Efient , launched in for patients with acute coronary syndrome ACS undergoing percutaneous coronary intervention PCI and edoxaban Lixiana , the first available factor Xa inhibitor in Japan, which launched in to help prevent venous thromboembolism VTE .
Quote | Daiichi Sankyo Co Ltd (OTCMKTS:DSKYF)
Last: | $35.90 |
---|---|
Change Percent: | 0.0% |
Open: | $35.9 |
Close: | $35.90 |
High: | $36.06 |
Low: | $35.9 |
Volume: | 1,222 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Daiichi Sankyo Co Ltd (OTCMKTS:DSKYF)
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
2024-06-27 07:56:32 ET More on Merck Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Tran...
Message Board Posts | Daiichi Sankyo Co Ltd (OTCMKTS:DSKYF)
Subject | By | Source | When |
---|---|---|---|
Dead boards are FUN!!!!!!!!!!!!!!!!!!!! | Termite7 | investorshub | 06/03/2018 8:44:59 PM |
http://3.bp.blogspot.com/-N2x8_K-MIXg/TeiCiJgsE3I/AAAAAAAAAdg/g1o_uek5nqM/s | KwikKash | investorshub | 08/27/2014 9:56:44 PM |
chartguy89: DSKYF 17.10 Stock Charts $DSKYF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 3:15:48 AM |
chartguy89: DSKYF Stock Charts Last: +0.77 Tuesday, February 25, 2014 at 12:27:12 PM $DSKYF | chartguy89 | investorshangout | 02/25/2014 5:27:24 PM |
Share Structure, Holders, and Other Information | Soapy Bubbles | investorshub | 06/11/2011 2:44:59 AM |
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...